Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance
18. November 2022 09:00 ET
|
Microbot Medical Inc.
HINGHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), in a continuation of its efforts to create barriers and expand its global intellectual property portfolio for...
Microbot Medical Announces New Webinar Series to Engage Stakeholders with Experts in the Healthcare Space
15. November 2022 07:00 ET
|
Microbot Medical Inc.
The “Access-Ability Live” by MBOT will build an online community of healthcare industry leaders who are interested in robotics to come together and share their opinion and experience First Webinar on...
Microbot Medical Receives Additional Patent Allowance in Israel for the LIBERTY® Robotic System
03. November 2022 07:00 ET
|
Microbot Medical Inc.
HINGHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to aggressively protect its global intellectual property (IP) portfolio for the LIBERTY® Robotic...
Microbot Medical Adds the Head of the Interventional Radiology Unit of Europe’s Largest Cancer Center, Dr. Thierry Jacques De Baère to its Scientific Advisory Board
31. Oktober 2022 07:00 ET
|
Microbot Medical Inc.
Growing SAB Roster Includes 11 KOLs from Across the U.S., Europe, and Israel Expansion of KOL Presence and Global Centers of Excellence Continues to Accelerate the Progression of the LIBERTY® Robotic...
Microbot Medical Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
25. Oktober 2022 16:01 ET
|
Microbot Medical Inc.
HINGHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering with a single...
Microbot Medical Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
21. Oktober 2022 08:00 ET
|
Microbot Medical Inc.
HINGHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into a definitive agreement with a single institutional investor for the...
Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the LIBERTY® Robotic System
18. Oktober 2022 08:45 ET
|
Microbot Medical Inc.
HINGHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it has submitted the anticipated follow-up pre-submission package for the LIBERTY® Robotic...
Microbot Medical Completes GLP Animal Study for the LIBERTY® Robotic System
13. Oktober 2022 09:15 ET
|
Microbot Medical Inc.
HINGHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY® Robotic...
Microbot Medical Enhances Strategic Focus on its Endovascular Solutions
11. Oktober 2022 09:00 ET
|
Microbot Medical Inc.
HINGHAM, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has announced that, following the recent acquisition of the endovascular assets of Nitiloop Ltd. along with...
Microbot Medical Receives Patent Allowance in Israel for the LIBERTY® Robotic System
10. Oktober 2022 07:00 ET
|
Microbot Medical Inc.
HINGHAM, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is continuing to expand its global intellectual property portfolio for the LIBERTY® Robotic System as a patent...